Cargando…

Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer

PURPOSE: The role of lymph node ratio (LNR, ratio of metastatic to examined nodes) in the staging of multiple human malignancies has been reported. We aim to evaluate its value in salivary gland cancer (SGC). METHODS: Records of SGC patients from Surveillance, Epidemiology, and End Results database...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Bo-Wen, Hu, Jia-Qian, Yu, Peng-Cheng, Wang, Yu-Long, Wei, Wen-Jun, Zhu, Ji, Shi, Xiao, Qu, Ning, Lu, Zhong-Wu, Ji, Qing-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858905/
https://www.ncbi.nlm.nih.gov/pubmed/31511971
http://dx.doi.org/10.1007/s00405-019-05597-0
_version_ 1783471047687798784
author Lei, Bo-Wen
Hu, Jia-Qian
Yu, Peng-Cheng
Wang, Yu-Long
Wei, Wen-Jun
Zhu, Ji
Shi, Xiao
Qu, Ning
Lu, Zhong-Wu
Ji, Qing-Hai
author_facet Lei, Bo-Wen
Hu, Jia-Qian
Yu, Peng-Cheng
Wang, Yu-Long
Wei, Wen-Jun
Zhu, Ji
Shi, Xiao
Qu, Ning
Lu, Zhong-Wu
Ji, Qing-Hai
author_sort Lei, Bo-Wen
collection PubMed
description PURPOSE: The role of lymph node ratio (LNR, ratio of metastatic to examined nodes) in the staging of multiple human malignancies has been reported. We aim to evaluate its value in salivary gland cancer (SGC). METHODS: Records of SGC patients from Surveillance, Epidemiology, and End Results database (SEER, training set, N = 4262) and Fudan University Shanghai Cancer Center (FUSCC, validating set, N = 154) were analyzed for the prognostic value of LNR. Kaplan–Meier survival estimates, the Log-rank χ(2) test and Cox proportional hazards model were used for univariate and multivariate analysis. Optimal LNR cutoff points were identified by X-tile. RESULTS: Optimal LNR cutoff points classified patients into four risk groups, R0, R1 (≤ 0.17), R2 (0.17–0.56) and R3 (> 0.56), corresponding to 5-year cause-specific survival in SEER patients of 88.6%, 57.2%, 53.1% and 39.7%, disease-free survival in FUSCC patients of 69.2%, 63.3%, 34.6% and 0%, and disease-specific survival in FUSCC patients of 92.3%, 90.0%, 71.4% and 0%, respectively. Compared with TNM staging, TNM + R staging showed smaller AIC values and higher C-index values in the Cox regression model in both patient sets. CONCLUSIONS: LNR classification should be considered as a complementary system to TNM staging and LNR classification based clinical trials deserve further research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00405-019-05597-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6858905
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-68589052019-12-03 Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer Lei, Bo-Wen Hu, Jia-Qian Yu, Peng-Cheng Wang, Yu-Long Wei, Wen-Jun Zhu, Ji Shi, Xiao Qu, Ning Lu, Zhong-Wu Ji, Qing-Hai Eur Arch Otorhinolaryngol Head and Neck PURPOSE: The role of lymph node ratio (LNR, ratio of metastatic to examined nodes) in the staging of multiple human malignancies has been reported. We aim to evaluate its value in salivary gland cancer (SGC). METHODS: Records of SGC patients from Surveillance, Epidemiology, and End Results database (SEER, training set, N = 4262) and Fudan University Shanghai Cancer Center (FUSCC, validating set, N = 154) were analyzed for the prognostic value of LNR. Kaplan–Meier survival estimates, the Log-rank χ(2) test and Cox proportional hazards model were used for univariate and multivariate analysis. Optimal LNR cutoff points were identified by X-tile. RESULTS: Optimal LNR cutoff points classified patients into four risk groups, R0, R1 (≤ 0.17), R2 (0.17–0.56) and R3 (> 0.56), corresponding to 5-year cause-specific survival in SEER patients of 88.6%, 57.2%, 53.1% and 39.7%, disease-free survival in FUSCC patients of 69.2%, 63.3%, 34.6% and 0%, and disease-specific survival in FUSCC patients of 92.3%, 90.0%, 71.4% and 0%, respectively. Compared with TNM staging, TNM + R staging showed smaller AIC values and higher C-index values in the Cox regression model in both patient sets. CONCLUSIONS: LNR classification should be considered as a complementary system to TNM staging and LNR classification based clinical trials deserve further research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00405-019-05597-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-09-11 2019 /pmc/articles/PMC6858905/ /pubmed/31511971 http://dx.doi.org/10.1007/s00405-019-05597-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Head and Neck
Lei, Bo-Wen
Hu, Jia-Qian
Yu, Peng-Cheng
Wang, Yu-Long
Wei, Wen-Jun
Zhu, Ji
Shi, Xiao
Qu, Ning
Lu, Zhong-Wu
Ji, Qing-Hai
Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title_full Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title_fullStr Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title_full_unstemmed Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title_short Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
title_sort lymph node ratio (lnr) as a complementary staging system to tnm staging in salivary gland cancer
topic Head and Neck
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858905/
https://www.ncbi.nlm.nih.gov/pubmed/31511971
http://dx.doi.org/10.1007/s00405-019-05597-0
work_keys_str_mv AT leibowen lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT hujiaqian lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT yupengcheng lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT wangyulong lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT weiwenjun lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT zhuji lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT shixiao lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT quning lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT luzhongwu lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer
AT jiqinghai lymphnoderatiolnrasacomplementarystagingsystemtotnmstaginginsalivaryglandcancer